RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
June 20 2023 - 7:30AM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
clinical-stage biopharmaceutical company developing targeted
combination therapies, today announced the appointment of Margaret
A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the
UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory
Board (SAB).
“Dr. Tempero has been an international leader in the field of
pancreatic cancer for decades and we look forward to working with
her alongside the other members of our SAB,” said Dr. Robert
Spiegel, NCI-trained oncologist, former Chief Medical Officer of
Schering Plough and RenovoRx Board Director.
Dr. Tempero is Professor of Medicine, Division of Hematology and
Oncology, at UCSF. She also serves as Chair of the NCCN Guidelines
Panel on Pancreatic Cancer (since 2000), editor-in-chief of JNCCN,
and on the ASCO Conquer Cancer Foundation Board. Previously, Dr.
Tempero has served on the ASCO Board of Directors, as ASCO
President, and as a member of FDA’s Oncology Drug Advisory
Committee. She co-directed the AACR/ASCO Methods in Clinical Cancer
Research and taught this course and similar courses in Europe and
Australia. She was founding Chair of the NCI Clinical Oncology
Study Section (CONC) and served as a member and Chair of the NCI
Board of Scientific Counselors Subcommittee A.
Dr. Tempero has served on the Scientific Advisory Boards of the
Lustgarten Foundation, the Pancreatic Cancer Action Network, the V
Foundation, The Alberta Canada Cancer Board and the EORTC. She has
served as Deputy Director and Interim Director for the University
of Nebraska Medical Center Eppley Cancer Center. She is Chief
Emeritus of the Division of Medical Oncology at UCSF and served as
the founding Deputy Director and Director of Research Programs at
the UCSF Helen Diller Family Comprehensive Cancer Center.
“We are honored to welcome Dr. Tempero to RenovoRx’s SAB, as we
enter a significant moment in the development of our first product
candidate, RenovoGem™ for patients with locally advanced pancreatic
cancer,” said Shaun Bagai, CEO, RenovoRx. “We look forward to
leveraging the SAB's breadth and depth of expertise, as we advance
our proprietary delivery platform and RenovoGem in our pivotal
Phase III clinical trial as a potential practicing-changing therapy
for cancer patients, beginning in pancreatic cancer.”
RenovoRx reported Phase III study interim analysis results at
the 2023 American Association of Clinical Research Annual Meeting
observing a 6-month median overall survival difference and 65%
reduction in side effects for patients on RenovoGem versus the
current standard of care in the locally advanced setting.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing targeted combination therapies for high unmet medical
needs. The company’s proprietary Trans-Arterial Micro-Perfusion
(TAMP™) therapy platform is designed to bypass traditional systemic
delivery methods and ensure precise therapeutic delivery to a
target tissue, while minimizing a therapy’s systemic toxicities.
RenovoRx’s unique approach to drug-delivery offers the potential
for increased treatment safety, tolerance, and wider therapeutic
windows. The company’s lead product candidate, RenovoGem™, combines
gemcitabine with the company’s patented delivery system and is
regulated by FDA under its 505(b)2 pathway. RenovoGem is currently
in a Phase III clinical trial (TIGeR-PaC) for the treatment of
LAPC. RenovoRx is committed to transforming the lives of patients
by delivering innovative solutions to change the current paradigm
of cancer care. For more information, visit www.renovorx.com.
Follow RenovoRx on Facebook, LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230620956139/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto or Jack Perkins T:212-896-1254 renovorx@kcsa.com
Media Contact: Kimberly Ha T: 9172915744
kimberly.ha@kkhadvisors.com
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From May 2024 to Jun 2024
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From Jun 2023 to Jun 2024